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Immune System – Part III
The delicate balance of the immune system 
between tolerance and autoimmunity
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ABSTRACT
The immune system consists of an intricate network of organs, cells, and molecules responsible for maintaining the 
body’s homeostasis and responding to aggression in general. Innate immunity operates in conjunction with adaptive 
immunity and is characterized by rapid response to aggression, regardless of previous stimulus, being the organism 
first line of defense. Its mechanisms include physical, chemical and biological barriers, cellular components, as well as 
soluble molecules. The organism first line of defense against tissue damage involves several steps closely integrated and 
constituted by different components of this system. The aim of this review is to restore the foundations of this response, 
which has high complexity and consists of several components that converge to articulate the development of adaptive 
immune response. We selected some of the following steps to review: perception and molecular recognition of aggres-
sive agents; activation of intracellular pathways, which result in vascular and tissue changes; production of a myriad of 
mediators with local and systemic effects on cell activation and proliferation, synthesis of new products involved in the 
chemoattraction and migration of  cells specialized in destruction and removal of offending agent; and finally,  tissue 
recovery with restoration of functional tissue or organ.
Keywords: innate immunity, inflammation, autoimmunity, PAMPs, Toll-like receptors.
INTRODUCTION
A loss of the ability of the immune system of an individual 
to distinguish between self and non-self is observed in organ-
specific and systemic autoimmune disorders. This ability, 
known as self-tolerance, is maintained in immunocompetent 
B and T cells both through central and peripheral mechanisms.
Loss of self-tolerance can have intrinsic or extrinsic cau-
ses. Intrinsic causes, i.e., those related to characteristics of 
the individual, are usually associated with polymorphisms in 
histocompatibility molecules, components of innate immunity, 
such as the Complement system and Toll-like receptors, com-
ponents of acquired immunity, such as regulatory lymphocytes 
and cytokines, and hormonal factors, which are under genetic 
control. Environmental factors, such as bacterial and viral 
infections, exposure to physical and chemical agents, such as 
UV radiation, pesticides, and drugs, are examples of extrinsic 
causes.
Epidemiological studies have shown the importance of 
genetic factors in determining susceptibility to autoimmune 
RBR 50 - 6.indb   679 16/12/2010   15:03:19
Souza et al.
680 Bras J Rheumatol 2010;50(6):665-94
diseases. Besides familial aggregation, the concordance rate 
of autoimmune disorders is greater in monozygotic than in 
dizygotic twins. However, even in genetically susceptible 
individuals, a “trigger agent” is usually necessary for the deve-
lopment of autoreactivity. Loss of tolerance is a multifactorial 
process in which both intrinsic and extrinsic factors concur.
The role of individual susceptibility determined by genetic 
factors is evident in the association of the HLA-B27 allele with 
ankylosing spondylitis, reactive arthritis, and psoriatic arthritis, 
as well as HLA-DRB1 alleles that contain the shared epitope 
with rheumatoid arthritis. The importance of the association 
of environmental and genetic factors can be evaluated, for 
example, in celiac disease, in which ingestion of gluten by 
a susceptible individual (with HLA-DQ2 and HLA-DQ8) 
leads to the production of autoantibodies and development 
of the disease.
Regarding extrinsic causes, several recent reviews on the 
role of infections in the development of autoimmune diseases1-3 
can be found in the literature, and associations between infec-
tions and exacerbation of autoimmune disorders are common. 
Infections can trigger loss of tolerance by several mechanisms. 
Among them are tissue damage and cellular necrosis, which 
expose cryptic epitopes in autoantigens or allow access of im-
munocompetent cells to normally isolated antigens; polyclonal 
T and B cell activation by microbial superantigens, such as 
toxins produced by S. aureus; activation of immunocompetent 
cells not directly involved in the response to pathogens, known 
as bystander activation; and molecular mimicry.
Rheumatic fever after group A streptococcus β-hemolytic 
infection, in which antibodies against streptococcal M pro-
tein that cross-react with cardiac tissue can be found in the 
serum of those patients, is the classical example of molecular 
mimicry.
The process of programmed cell death, apoptosis, is 
important both for maintenance of central and peripheral 
tolerance and in controlling lymphocyte populations ge-
nerated in the immune response. An increase in the rate of 
apoptosis can result in immunodeficiencies, and there is 
evidence that failure of apoptotic mechanisms or clearance 
of apoptotic cells can lead to the development of autoim-
munity and lymphomas. Apoptotic cells should be removed 
immediately by phagocytes, macrophages, and dendritic 
cells, preventing exposure of autoantigens. The crucial 
role of apoptosis in maintenance of lymphocyte population 
homeostasia can be evaluated in autoimmune lymphoproli-
ferative syndrome (ALPS), a rare human disorder. In those 
patients, mutations in the genes encoding proteins of the 
FAS apoptosis pathways are seen. Consequently, since 
lymphocytes do not undergo the usual process of apoptosis, 
there is progressive accumulation of these cells, resulting in 
lymphadenomegaly, hepatosplenomegaly, and autoreactive 
T lymphocytes. It is intriguing that autoimmune manifes-
tations in this syndrome are related, predominantly, to the 
hematologic system, especially autoimmune hemolytic 
anemia and thrombocytopenia.
At least in some of the patients with SLE, the deficiency 
in apoptotic cell clearance seems to contribute for the patho-
physiology of the disease. Genetic deficiencies of C1, C2, and 
C4 are associated with a greater prevalence of systemic lupus 
erythematosus, although the strength of this association is va-
riable for each of those elements. Thus, 90% of individuals with 
C1q deficiency should develop SLE, usually with significant 
renal involvement. C4 deficiency would be associated with the 
development of SLE in 75% of the cases; and those with C2 
deficiency can be asymptomatic, but a smaller proportion of 
those patients will develop SLE, although less severe.
Currently, evidence that innate immunity has an important 
role in the development of autoimmunity accumulates. The 
known relationship between Complement deficiencies and 
autoimmunity has been explained by the reduced clearance of 
immunocomplexes and apoptotic cells. Toll-like receptors that 
recognize pathogen-associated molecular patterns (PAMPs) 
represent another important link between innate and acquired 
immunity. Some of those receptors show specificity for nucleic 
acids, such as the autoantigens DNA and ribonucleoproteins. 
Inflammation triggered by innate immunity can stimulate the 
immune system, by a mechanism known as adjuvant effect. 
Inflammatory mediators induce expression of HLA class I and 
II molecules by cells in the damaged tissue, allowing those 
cells to work as antigen-presenting cells. In this situation, 
presentation of autoantigens in a context other than the usual, 
which might result in autoimmunity, is possible.
CENTRAL TOLERANCE OF T LYMPHOCYTES
Several aspects are relevant when considering the rupture of 
the mechanisms of tolerance, with consequent triggering and 
maintenance of autoimmune abnormalities. The multifactorial 
and polygenic nature of autoimmune disorders, with genes 
linked to disease susceptibility and others strictly linked to 
their severity is one of these aspects. Since the recombinant 
mechanisms of multiple gene segments responsible for coding 
immunoglobulins in B lymphocytes (BL) and TCR in T lym-
phocytes (TL) are random, receptors capable of recognizing 
self structures are most likely produced.
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T cell precursors, originated in the bone marrow, migrate 
to the thymus where they undergo sequential modifications 
characterizing the different stages of TL differentiation. In 
the initial maturation stage, cellular proliferation of lym-
phocytes occurs in the outermost cortex region, with TCR 
gene rearrangement and expression of CD3, TCR, CD4, and 
CD8 molecules on the cell surface. As thymocytes mature, 
they migrate from the thymic cortex to the medulla.4 The 
thymic stroma consists of epithelial cells, macrophages, and 
bone marrow-derived dendritic cells, besides fibroblasts and 
extracellular matrix molecules. The interaction of thymocytes 
and cells of the thymic microenvironment is fundamental for 
cell proliferation, differentiation, and expression of surface 
molecules, such as CD4 and CD8, and creation of the reper-
toire of TL receptors.5
Thymocytes that succeed in expressing the complete TCR 
molecule (αβ or γδ chains) undergo two distinct processes, 
positive selection followed by negative selection. Positive 
selection is based on usefulness criteria, mainly the affinity of 
the link between TCR and MHC complex (MHC restriction). 
Thymocytes undergo positive selection in the thymic cortex, 
where thymocytes with TCR capable of binding to the self-
peptide-MHC complex are stimulated to survive and continue 
the maturation process. Thymocytes whose receptors do not 
recognize the self-MHC molecules die by apoptosis, ensuring 
that TLs are restricted to self-MHC. Positive selection also 
associates restriction of class I and II MHC molecules to TL 
subtypes, ensuring the CD8+ T cells are specific for peptides 
exposed on Class I MHC molecules, while CD4+ T cells are 
specific for peptides exposed on class II MHC molecules. 
In negative selection, thymocytes whose TCRs show strong 
affinity for the self-peptide-MHC complex are eliminated, 
therefore avoiding maturation of autoreactive TLs. In theory, 
immunologic self includes all epitopes (antigenic determinants) 
coded by the DNA of the individual, so all other epitopes are 
recognized as non-self.
During the development of thymocytes, the majority of 
those cells die by apoptosis (around 95%). This is due, mainly, 
to unsuccessful rearrangements of TCR chains and positive 
and negative selections, and only a small fraction (3% to 5%) 
will become mature TLs (Figure 1).
However, recent studies suggest that not all thymocytes 
with high affinity for autoantigens are destroyed by negati-
ve selection in the thymus. Some median- and high-affinity 
thymocytes survive and undergo a process known as non-
deletional central tolerance that leads to the generation of 
immunosuppressor CD4+ T cells, known as naturally-occurring 
regulatory T cells or TREGs.
6
Figure 1
A. Schematic representation of positive and negative 
selections for T cells in the thymus. Double-positive thy-
mocytes are in contact with self-peptides linked to MHC 
molecules on epithelial cells, in the thymic cortex, and on 
macrophages and dendritic cells, in the thymic medulla. 
Thymocytes whose TCRs are incapable of recognizing 
self MHC and peptides die by apoptosis (positive selec-
tion). Thymocytes whose TCRs have high affinity for 
self MHC and peptides are removed by apoptosis (ne-
gative selection). B. Schematic representation of central 
and peripheral tolerance mechanisms of B lymphocytes. 
Immature lymphocytes that show high affinity for self 
antigens in the bone marrow are eliminated by apopto-
sis (1) or undergo change of their antigenic specificity 
(2). Non-specific lymphocytes for self antigens and that 
underwent recombination (3) migrate into the periphery. 
Cells that encounter auto-antigens in the periphery and are 
activated are eliminated by apoptosis or become anergic. 
On the other hand, those that do not show specificity for 
self antigens are capable of generating an immune response 
when they encounter foreign antigens.
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PERIPHERAL TOLERANCE OF T LYMPHOCYTES
Immunologic tolerance of TLs to self-antigens occurs, mainly, 
in the thymus. Cells that reach the periphery should be im-
munocompetent against non-self-antigens, but incapable of 
developing an immune response against self-antigens; however, 
this is not what is seen. Several studies7 have shown that small 
numbers of autoreactive cells are present in individuals without 
autoimmune disorders and they can be isolated from peripheral 
blood and lymphoid tissues. These observations have shown that 
autoreactive TLs that manage to evade the barriers of tolerance 
mechanisms and leave primary lymphoid organs can be found 
in the periphery.8 Therefore, thymic deletion of autoreactive 
TLs is not the only mechanism responsible for self-tolerance; 
its maintenance also involves the interaction of several peri-
pheral immunologic mechanisms that operate continuously. 
Peripheral immunologic tolerance is organized in different and 
redundant mechanisms, such as immunological ignorance, dele-
tion, inhibition, or suppression of autoreactive clones (Figure 2).
Immunological ignorance can be due to physical separation 
between antigens and TLs, such as that seen in the blood-brain 
barrier, or to insufficient levels of antigens to activate the res-
pective TLs. Another mechanism, much more important, con-
sists on antigen presentation in the absence of a co-stimulator 
or “second signal”. In this situation, failure of TL activation 
occurs, leading to anergy or cell death by apoptosis.
Programmed death of TLs by apoptosis is triggered by the 
extrinsic apoptosis pathway involving the Fas molecule and its 
ligand (FasL). Increased expression of the Fas ligand in APCs 
presenting antigens can induce apoptosis of TLs through acti-
vation of the Fas molecule. Defects in TL signaling activation 
pathways associated with resistance to apoptosis apoptosis 
may lead to the persistence of autoreactive TL clones in the 
peripheral circulation.
As mentioned before, an important mechanism of peri-
pheral tolerance consists of the absence of a co-stimulatory 
signal necessary for activation of TLs, besides the primary 
Figure 2
Peripheral tolerance and induction mechanisms. T cells phy-
sically separated from their specific antigens, for example, by 
the blood brain barrier, cannot be activated, which is known 
as immunologic ignorance. T cells that express CD95 (FAS) 
on their surface can receive apoptosis induction signals from 
cells that express FAS-L, which is referred as deletion. One 
example of inhibition can be observed in the binding of CD152 
to CD80 on APCs, inhibiting T cell activation. Regulatory T 
cells can inhibit or suppress other T cells, probably by produ-
cing inhibitory cytokines, such as IL-10 and TGF-β.
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signal furnished by the binding between the TCR and the 
MHC-antigen complex. This secondary signal is obtained, 
mainly, by the interaction between the CD28 molecule on 
the surface of TLs and the B7 molecule family (CD80 and 
CD86), expressed on the surface of antigen-presenting cells 
(APCs). In the presence of pathogens, APCs are activated and 
increase the expression of B7 molecules to a high enough level 
to provide the second signal and production of IL-2 by TLs.9 
In physiologic conditions and absence of inflammation, low 
levels of B7 molecules in APCs hinder complete activation 
of autoreactive TLs, favoring anergy or apoptosis when they 
encounter the antigens for which they are specific.
Inhibition of TLs can also be achieved by binding a B7 
family co-stimulatory-competing molecule. In specific situa-
tions, APCs express CTL-4 (CD152) molecules, which have 
greater affinity for CD28 than B7 molecules (CD86 and CD80). 
However, unlike those molecules, CTLA-4 inhibits TLs, 
inducing apoptosis. In mice, blocking the CTLA-4 molecule 
accelerates the progression of autoimmune diabetes.
Mechanisms of immunosuppression also include several 
immunoregulatory cell populations whose basic characteristic 
is the capacity to produce immunosuppressor cytokines, such 
as IL-4, IL-10, and mTGF-β, besides being able to induce cell-
cell contact-mediated suppression through surface molecules, 
such as CTLA-4. Immunoregulatory cells are involved in the 
modulation and control of pathogen elimination processes in 
places with tissue destruction , exposure of autoantigens, and 
production of proinflammatory cytokines, conditions that favor 
induction and maintenance of autoimmune events that need to 
be controlled. These cells work in a complex network of regula-
tory mechanisms aimed at ensuring modulation of immunologic 
responses in face of several antigens derived of  infectious 
processes, tumors, alloantigens, autoantigens, and allergens.
Naturally-occurring regulatory T cells (TREGs, CD4+ CD25+ 
CD127Low, Foxp3+), first described by Sakaguchi et al., TRI 
cells, which regulate by producing IL-10 and suppress the 
development of some TL responses in vivo,11 and TH3 cells, 
capable of suppressing target-cells by producing TGF-β,12 are 
among the immunoregulatory TLs. Several other regulatory 
cells, such as CD8+CD28- TLs, NK-T cells, Tδγ cells, double-
negative TLs, CD8+Qa1+ TLs, and CD1+ B cells, also exist, 
Figure 3 shows the main immunoregulatory cells.
The relevance of regulatory cell populations in autoimmune 
rheumatic diseases has been demonstrated in murine models, in 
which the absence or depletion of TREG cells triggers systemic 
autoimmune diseases with elevated titers of antinuclear anti-
bodies, as well as organ-specific autoantibodies.14 Important 
findings, such as functional, phenotypic, and quantitative 
Figure 3
Schematic representation of the main immunoregulatory cells 
responsible for maintaining the mechanisms of peripheral 
tolerance.
defects of regulatory cells, have been reported in several 
human autoimmune rheumatic disorders, demonstrating their 
important role in the maintenance of immunologic tolerance 
and in the pathophysiological mechanisms of these disorders.
Studies of immunoregulatory T cells have been undertaken 
in disorders like rheumatic arthritis, systemic lupus erythe-
matosus, mixed connective tissue disease, primary Sjögren 
syndrome, Kawasaki disease, and Wegener’s granulomatosis. 
In these disorders, quantitative changes in these cells have 
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been observed in affected tissues and/or peripheral circulation, 
functional defects, target-cell resistance to suppression, and 
even normal frequency and function. Conflicting results in 
the literature are most likely a consequence of the conceptual 
and technical evolution in this field, leading to heterogenous 
methodological approaches among different studies, with the 
consequent discrepancy in results.
It is hoped that studies currently under way can elucidate 
more accurately the exact role of regulatory cells in different 
disorders and the real role of functional and quantitative 
changes in these cells in the rupture of tolerance seen in au-
toimmune diseases. Due to the multifactorial and multigenic 
characteristics, as well as the clinical heterogeneity of each 
autoimmune rheumatic disease, that are more like syndromes 
than nosological entities, the finding of numeric and/or functio-
nal changes in just a fraction of patients with a given disorder 
should not be surprising.
EFFECTOR T LYMPHOCYTES 
AND AUTOIMMUNITY
Approximately 20 years ago, based on the cytokines produced, 
effector CD4+ TLs were divided in two distinct subtypes, T 
helper 1 (Th1) and T helper 2 (Th2) cells. Some authors also 
favored the existence of a third cell population, Th0 cells, 
represented by undifferentiated lymphocytes capable of produ-
cing Th1 and Th2 cytokine profiles. Currently, it is clear that, 
after antigenic stimulation, naïve CD4+ TLs proliferate and 
differentiate, according to the local cytokine environment, in 
different effector subtypes with different characteristics (Th1, 
Th2, Th3, TREG, Th17), determined by their cytokine profile 
and functional properties.
As shown in Figure 4, Th1 cells are characterized, mainly, 
by the production of large quantities of IFN-γ, while Th2 cells 
produce IL-4, IL-5, and IL-13. T helper 1 response triggers late 
hypersensitivity mechanisms, activates macrophages, and are 
very efficient in eliminating intracellular pathogens. T helper 
2 cells are more effective in helping the immune humoral 
response, triggering the production of immunoglobulins and 
eosinophilic inflammation responses, important in fighting 
extracellular pathogens. T helper 0 lymphocytes differentia-
te into Th1 or Th2 on an early stage of cellular activation. 
Characteristically, Th1 or Th2 cytokine profile direct the 
development of their own pathway, inhibiting expression of 
the opposite pattern. Thus, once the immune response is pola-
rized into Th1 pattern, the Th2 pathway will be inhibited and 
vice-versa. This is due to regulation of the level of membrane 
Figure 4
Schematic representation of the different TH0 differentiation 
pathways emphasizing cytokines that induce Th1, Th2, Th17, 
and TREG differentiation and the main cytokines produced.
receptors, differential expression of transcription factors, and 
epigenetic changes.4
Unregulated, or exacerbated, immune effector responses 
can lead to the development of allergic and autoimmune di-
sorders. T helper 1 cells are potentially proinflammatory and 
they have been associated with induction and progression of 
autoimmune diseases. However, studies with transgenic mice 
with deficiencies of IFN-γ or its receptor have shown that the 
loss of signaling associated with IFN-γ does not render one 
resistant to the development of autoimmunity. On the contrary, 
those animals are more susceptible. Since IFN-γ is one of the 
main Th1 cytokines, those observations lead to questioning 
of the exclusive role of Th1 cells in the pathophysiology of 
autoimmune diseases, leading to the search of other subtypes 
of TLs, distinct from Th1 cells, capable of inducing tissue 
inflammation and autoimmunity.
The need to understand the immunologic mechanisms 
responsible for tissue lesions on several chronic inflammatory 
disorders, and the development of studies on effector TL po-
pulations lead to the characterization of IL-17-producing TLs, 
called Th17.15 Recent studies have demonstrated that the spe-
cific subpopulation of IL-17-producing CD4+ T lymphocytes, 
more than Th1 cells, have a central role in the pathogenesis of 
experimental models of autoimmune diseases.
Studies on autoimmune disorders, such as rheumatoid 
arthritis, systemic lupus erythematosus, psoriasis, multiple 
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sclerosis, systemic sclerosis, inflammatory bowel disease, 
ankylosing spondylitis, and juvenile idiopathic arthritis, de-
monstrated the presence of elevated levels of inflammatory 
products related to the Th17 effector pathway or even their 
direct participation on pathophysiological mechanisms.
Current concepts on the immunopathology of chronic in-
flammatory diseases indicate a central role of Th17 cells, which 
would be responsible for mediating early tissue inflammation, 
producing proinflammatory cytokines and chemokines respon-
sible for recruiting Th1 cells to sites of inflammation. Even 
though T regulatory cells (TREGs) can also accumulate in those 
sites, the presence of inflammatory cytokines renders target 
cells less susceptible to immunomodulation and decreases the 
immunosuppressive power of TREG cells. Recent studies have 
demonstrated a great flexibility in the differentiation process 
of CD4+ TLs, and the existence of a close relationship between 
the Th17 pathway and Th1 and TREG pathways does exist.
16 
Depending on the stimulus and environmental conditions, Th17 
cells can differentiate into either Th1 or TREG cells, changing 
significantly the end-result of the immune response.16 In the 
current context, a new subpopulation of effector TLs, Th9 cells, 
has been proposed.17 Murine Th9 lymphocytes have recently 
been described as cells that produce large quantities of IL-9, 
an important cytokine in the responses against intestinal para-
sites.18 It has also been demonstrated that they result from the 
polarization of Th2 lymphocytes stimulated in the presence 
of TGF-β and IL-4, and that they do not present none of the 
transcription factors characteristic of Th1, Th2, Th17, or TREG 
cells.17 The role of IL-9 in the pathophysiology of chronic 
allergic conditions has been well documented; however, little 
is known on the role of those cells in different human diseases.
Understanding those differentiation pathways and their 
imbalances in different autoimmune disorders will help in the 
development of therapeutic strategies aimed at broadening the 
action of regulatory cells, along with the control of effective 
inflammatory response.
CENTRAL B LYMPHOCYTE TOLERANCE
When membrane immunoglobulins, BL receptors, are ex-
pressed by the first time, when those cells are still in the bone 
marrow, autoreactive receptors can be produced as consequen-
ce of the random repertoire-generating process. To avoid the 
release of autoreactive BLs into the periphery, mechanisms 
of central tolerance exist and, in case they fail in eliminating 
those lymphocytes, peripheral tolerance mechanisms also exist. 
Deficiencies in those mechanisms can lead to the development 
of autoimmunity.
Immature BLs that show high affinity for self-antigens in 
the bone marrow are eliminated or undergo reactivation of 
RAG1 and RAG2 genes (which cause somatic hypermutation 
of hypervariable regions in the immunoglobulin genes) and 
express a new immunoglobulin chain, therefore showing new 
antigenic specificity. This process is known as receptor editing, 
and is an important mechanism through which occasional au-
toreactive BLs will lose their autoreactivity. If receptor editing 
fails in eliminating autoreactivity, cells are usually eliminated 
by apoptosis (Figure 1B). Occasionally, BLs that recognize 
self antigens can leave for the periphery, but they show low 
expression of membrane immunoglobulins.
PERIPHERAL TOLERANCE OF B LYMPHOCYTES
When occasional autoreactive mature BLs encounter soluble 
autoantigens in the periphery, in the absence of helper TLs, 
i.e., of the second activation signal, they become anergic, being 
incapable of responding after new encounters with the antigen. 
If an anergic BL encounters an activated helper TL, it can be 
eliminated by the interaction between BL Fas and TL FasL. 
In the absence of normal co-stimulatory pathways, anergic B 
lymphocytes show greater sensitivity to apoptosis after binding 
of Fas to its ligand (FasL). In this context, chronic exposure to 
autoantigens in physiological environment (non-inflammatory 
conditions) can contribute to tolerance maintenance.
B lymphocytes that encounter autoantigens in the periphery 
cannot home into lymphoid follicles, probably due to failure 
in the expression of adequate chemokine receptors. There is 
evidence of the existence of peripheral tolerance mechanisms 
for BLs that develop autoreactive specificities, as result of 
somatic hypermutation, during the response to a non-self an-
tigen, in germ centers. In this case, it has been hypothesized 
that elevated local antigen concentrations would lead those 
clones to apoptosis.
All these mechanisms emphasize the fact that the mere 
existence of autoreactive BLs is not, in itself, damaging. Before 
an immune response is initiated, BLs need to encounter their 
antigens, receive effective help from TLs, and its intracellu-
lar signaling machinery should be able of creating a normal 
response.
IDIOTYPIC NETWORK
The idiotypic network theory, introduced in the decade of 1970, 
is based on the reciprocal interaction among variable regions 
of the antibodies produced by an individual. The idiotope 
is the portion of the variable region of the immunoglobulin 
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molecule that interacts with the antigen. Each idiotope can 
behave as an antibody, when it encounters its antigen, and as 
an antigen, when facing an anti-idiotype antibody.19 One can 
imagine this scenario as an interconnected network of anti-
bodies with reciprocal reactivity for idiotopes, in such a way 
that a critical mass is formed, which contributes to the stability 
of the system. Extrinsic antigenic stimuli would represent a 
disturbance of this network, but they tend to be assimilated 
and return to their status quo.
In theory, the immune system would recognize, predomi-
nantly, itself, and the response to an antigen would be the result 
of the increase of a given antibody in the network, disturbing 
the homeostasis of the system. An increase in the first antibody, 
AB1, recognized by AB2, would lead to an increase of the latter 
that has a tendency to promote hyper-regulation of the former 
(AB1). The same would be seen regarding AB2, AB3, and so 
forth, always showing a tendency to restore the equilibrium 
of the system (Figure 5).
Recently, the interest on the study of idiotypic interactions, 
especially in the clinical context, such as in autoimmune 
diseases, has been renewed. In the last decade, idiotypic in-
teractions of T cells have received increased attention. It has 
been proposed that anti-idiotypic T cells behave as regulatory 
T cells, controlling autoimmune diseases. Recently, experi-
mental evidence has shown that idiotypic and anti-idiotypic 
T cells can coexist and form a dynamic idiotypic network in 
the same organism.20
Figure 5
Schematic representation of the idiotypic network. The do-
main formed by hypervariable regions of the immunoglobulin 
molecule (AB-1) characterizes the antigenic specificity of a 
given antibody, which is known as idiotope. Each idiotope 
is, in turn, recognized by an anti-idiotope antibody (AB-2), 
therefore forming an idiotype recognition network.
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Expressive therapeutic effects of the use of natural anti-
bodies (intravenous immunoglobulins) in autoimmune and 
inflammatory disorders represent the first example of clinical 
intervention based on those powerful regulatory interactions. 
It has been suggested that B cells and/or immunoglobulins can 
be used therapeutically to increase the diversity and restore the 
repertoire of TLs to improve its function in situations associated 
with a restricted repertoire.21 Thus, antibodies have a role not 
only in interaction and signaling among BLs, but they appa-
rently modulate the development, maintenance, and function 
of TLs. It is believed that autoimmune diseases can be related 
to deficiencies in the control of autoreactive antibodies by the 
idiotypic network. Immunomodulation of autoimmune and 
inflammatory disorders using intravenous immunoglobulins 
can have relevant therapeutic effects. Idiotypic interactions 
have been studied in myasthenia gravis and hemophilia A. 
Recently, an experimental therapy for type I diabetes, based 
on vaccines composed of idiotypic peptides, and vaccination 
with idiotypic and anti-idiotypic antibodies, for cancer, has 
been proposed.22
DENDRITIC CELLS AND AUTOIMMUNITY
Dendritic cells (DCs) are immune system cells whose main 
function is processing and presenting antigens to other cells, 
being considered the most important antigen-presenting 
cells (AOCs). Dendritic cells have a fundamental role in the 
maintenance of both central and peripheral tolerance.23,24 
Classically, DCs can be classified in two main subtypes, 
myeloid and plasmacytoid, that differ according to their 
origin, morphology, and products secreted. Myeloid DCs 
(mDCs) secret large quantities of IL-2 while plasmacytoid 
DCs (pDCs) secret IFN-α.
Dendritic cells can be found in the most variable anatomic 
sites and, once activated, they migrate to secondary lymphoid 
organs where they interact with TLs and BLs. Dendritic cells 
have a central role in immune responses, regulating their 
activation and progression.25 Since DCs should limit tissue 
damage while, at the same time, guaranteeing the ability 
to respond to pathogens, overall mechanisms of tolerance 
maintenance should work actively to maintain this fine 
equilibrium.
During viral infections, immunocomplexes containing 
DNA or RNA of apoptotic or necrotic cells are internalized 
by DCs and BLs, interacting with receptors TLR 7, 8, and 9, 
which, on their turn, will activate the production of Type I 
IFN. Plasmacytoid DCs, in particular, produce large quanti-
ties of type I IFN, which has a paracrine action on other DCs, 
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increasing even more immune activation (Figure 6). Several 
clinical observations confirmed the critical role of IFN-α in 
the etiopathogeny of autoimmune disorders, suggesting that 
induction of autoimmunity does not require, necessarily, factors 
like molecular mimicry, but it can be related to tissue dama-
ge and activation of innate immune response in susceptible 
individuals. Several evidences have shown that activation of 
DCs via Toll-like receptors (TLRs), in genetically susceptible 
individuals, can induce autoimmunity through the production 
of proinflammatory cytokines, especially type I interferons 
(IFN- α and IFN-β).26
DENDRITIC CELLS AD AUTOIMMUNE DISEASES
Dendritic cells are fundamental for the onset of immune res-
ponses and, in some autoimmune diseases, such as systemic 
lupus erythematosus (SLE), their immunostimulatory func-
tion is exacerbated, i.e., they are more effective in stimulating 
TL responses. Several studies have suggested that the blood 
of SLE patients behaves as an inductor of maturation and 
differentiation of DCs. Exposure of monocytes of healthy 
individuals to the serum of SLE patients results in fast genera-
tion of cells with DC morphology and function. In SLE, mo-
nocytes behave like DCs, inducing proliferation of allogeneic 
TLs, representing an important source of immunomodulatory 
mDCs. Since, in SLE, this function is inhibited by the use of 
anti-IFN-α antibodies, IFN-α seems to be the great inducer 
of maturation and differentiation of DCs. The main source 
of this cytokine are pDCs, and the most accepted mechanism 
to explain the elevated levels of IFN-α in the serum of SLE 
patients is the recognition of immunocomplexes, containing 
DNA or RNA of apoptotic or necrotic cells, that are inter-
nalized by pDCs, activating the IFN-α production pathway. 
Several clinical observations confirm the critical role of 
IFN-α on the etiopathogeny of SLE. Treatment of tumors or 
infectious diseases with IFN-α is frequently associated with 
induction of autoantibodies (4-19%), and a variety of SLE 
symptoms have been observed in those patients. Mutations 
in genes involved in the production of IFN-α/β predispose 
the development of SLE by increasing the ability of pDCs to 
release those cytokines after activation. Other diseases, such 
as autoimmune thyroiditis and diabetes, are also marked by 
the action of INF-α.27
In turn, rheumatoid arthritis and psoriasis are associated 
with the deleterious effects of TNF-α, a highly inflammatory 
cytokine that affects several cells and organ systems. It is 
believed that mDCs of those patients are important in the 
rupture of tolerance and exacerbation of TNF production 
Figure 6
Schematic representation of Th1, Th2, and Th17 cells, as well as 
the central role of dendritic cells (DCs) on triggering autoimmu-
ne responses. DCs can be activated by recognizing PAMPs, in 
the presence of infectious agents or other triggering factors, such 
as an inflammatory process. After activation, DCs can process 
and present auto-antigens, therefore activating clones of auto-
reactive T cells and polarizing the immune response into different 
pathways (Th1, Th2, or Th17). Once the process of tolerance 
rupture is initiated, inflammatory response, stimulated by type I 
IFNs and other proinflammatory cytokines, will be perpetuated 
and auto-reactive clones will be maintained.
stimulated by recognition of autoantigen-containing 
complexes.26
Learning the proper manipulation of the behavior of those 
cells in different disorders is one of the challenges of modern 
immunology. If we succeed, those efforts will represent a 
valuable treatment alternative, either to induce immunity or 
to recover tolerance.
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IMMUNOBIOLOGICALS
Immunobiological therapies used includes, mainly, cytoki-
nes, monoclonal antibodies, and soluble cytokine receptors. 
Several cytokines and their receptors, adhesion molecules, 
and cells that participate in the immune response, such as B 
and T lymphocytes, represent the targets of immunobiolo-
gical therapy. Immunobiological therapy is used in different 
medical subspecialties including rheumatology, oncology, 
hematology, gastroenterology, neurology, and nephrology, 
among others.28,29
Monoclonal antibodies used usually belong to IgG class and 
receive the suffix “mab”, derived from the expression mono-
clonal antibody. This suffix varies according to the constitution 
of the non-variable portion of the monoclonal antibody. If it 
is a murine antibody, the suffix “omab” is used (for example, 
edrecolomab); if it is chimeric, i.e., with approximately 30% 
of murine molecule and 70% of human molecule, the suffix 
used is “ximab” (for example, infliximab); if it is humanized, 
and less than 10% of the monoclonal antibody is murine in 
origin, the suffix “zumab” is used (for example, epratuzumab); 
and if the antibody is completely human, the suffix “umab” is 
used (for example, adalimumab). Soluble cytokine receptors 
are fusion proteins (recombinant) composed by the receptor in 
question associated with the Fc portion of IgG1, and the suffix 
used is "cept" (for example, etanercept).30
Below, we will review immunobiological therapy applied 
to soluble mediators of the immune response and T and B 
lymphocytes used, especially in autoimmune disorders.
Biological therapy and cytokines
Biological agents can be used to inhibit the effects of 
cytokines, as seen with monoclonal anti-cytokine antibodies, 
or soluble receptors that bind cytokines and block their effects 
in target-cells. Cytokines can also be used in biological therapy 
through recombinant analogue proteins that mimic the effects 
of the original cytokine.
Proinflammatory cytokines, such as interleukin-1 (IL-1), 
TNF-α, and IL-6, are the main targets of anti-cytokine therapy, 
while the use of type I interferons is the main application of 
cytokine agonist therapy.
Anakinra is a non-glycosilated recombinant analogue 
of IL-1 receptor antagonist (IL-1Ra). Interleukin-1 receptor 
antagonist can be classified as a counter regulatory cytokine 
produced during inflammation, in response to the production 
of IL-1, which competes with IL-1β for type I IL-1 receptors, 
inhibiting its biologic effects.29
This agent was initially investigated, in several clinical 
assays, in rheumatoid arthritis (RA) and it was approved by 
the FDA (Food and Drug Administration), in 2001, for cases 
refractory to one or more DMARDs (disease-modifying anti-
rheumatic drugs). However, the true role of anakinra in RA 
has yet to be determined, especially after the advent of other 
biological agents.31 Nonetheless, new studies have demonstra-
ted good results when it is used in individuals with diabetes 
mellitus, acute gout, adult Still’s disease, systemic form of ju-
venile idiopathic arthritis, and in autoinflammatory syndromes, 
such as familial Mediterranean fever, TRAPS (tumor necrosis 
factor receptor-associated periodic syndrome), Muckle-Wells 
syndrome, and Schnitzler syndrome.32,33,34
Two new IL-1 antagonist agents, canakinumab and rilona-
cept, have been recently used in the treatment of rare diseases. 
Canakinumab is an anti-IL-1β human monoclonal antibody 
released in Europe and United States to treat the systemic 
form of juvenile idiopathic arthritis and cryopyrinopathies 
(autoinflammatory syndromes associated with defects of 
cryopyrin or pyrin genes). Rilonacept, known as IL-1Trap, is 
a fusion protein composed of the type I receptor of IL-1, the 
accessory protein of the IL-1 receptor, and the Fc fraction of 
human IgG1. Rilonacept binds and neutralizes circulating IL-1 
before it binds to its receptors on the cell surface. It has been 
investigated in patients with autoinflammatory syndromes and 
in acute gout with good results.35
Anti-TNF-α agents represent the main biological agents 
currently used in rheumatology. Its main representatives in-
clude etanercept, infliximab, and adalimumab. Etanercept is 
a dimer that includes the p75 TNF receptor linked to the Fc 
fraction of IgG. It binds TNFα molecules, circulating or bound 
to effector cells, inhibiting the binding to its receptor and pre-
venting the biologic effects of TNFα and TNFβ (lymphotoxin), 
but it does not cause cytotoxicity of cells that express TNFα 
on their surface.36
Infliximab is a chimeric anti-TNFα monoclonal antibody, 
i.e., it has a portion of human IgG1κ and a Fγ region from 
neutralizing murine antibodies with high affinity for human 
TNFα. Infliximab binds both free TNFα and TNFα bound to 
the cell surface, inducing lysis of those cells by antibody-
mediated cytotoxicity. Unlike etanercept, infliximab does not 
bind TNF-β. Adalimumab is an anti-TNFα IgG1 recombinant 
human monoclonal antibody with a prolonged half-life, requi-
ring subcutaneous administration every two weeks.36
Etanercept, infliximab, and adalimumab have been well 
investigated and approved for treatment of RA, juvenile idio-
pathic arthritis, ankylosing spondylitis (AS), and psoriatic 
arthritis. Infliximab and adalimumab have shown to be effective 
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in controlling disease activity and maintenance of remission in 
Crohn’s disease (CD), while infliximab seems to be the only 
agent effective in controlling CD-associated fistulae. A second 
generation of anti-TNFα agents is currently being evaluated 
in different studies. Those agents include certolizumab pegol 
and golimumab.37,38
Certolizumab pegol (CDP870) is the pegylated fragment 
of the Fb portion of a humanized anti-TNFα monoclonal anti-
body whose efficacy in the treatment of RA and CD has been 
demonstrated. Due to its long half-life, certolizumab pegol can 
be administered subcutaneously once a month.39 Golimumab 
is an anti-TNFα human  monoclonal antibody that has been 
evaluated in patients with RA, psoriatic arthritis, and ankylo-
sing spondylitis (AS) with good results.40,41,42
Lenercept and CDP571 are anti-TNFα agents that did not 
demonstrate clinical benefits in the treatment of disorders like 
as CD and RA, and its development has been discontinued. 
Pergsunercept was evaluated in patients with RA and showed 
to be superior to placebo only in one phase II study. Onercept 
is the recombinant TNFα soluble receptor p55 that has been 
under investigation in the treatment of moderate to severe 
psoriasis. This agent did not show to be effective in CD in-
duction therapy.29
Interleukin-6 (IL-6) is a cytokine whose actions affect 
different cells and high levels can be observed in several 
inflammatory diseases. It stimulates hepatocytes to produce 
acute phase proteins, such as C reactive protein, fibrinogen, 
and amyloid A protein, while at the same type it reduces the 
production of albumin. Recently, it has been described that 
IL-6 stimulates production of the peptide hepcidin that parti-
cipates in the pathogeny of inflammation-associated anemia. 
Tocilizumab, a humanized monoclonal antibody against the 
soluble IL-6 receptor, inhibits the proinflammatory effects of 
this cytokine. Clinical assays have demonstrated the efficacy of 
this biological agent in the treatment of RA, juvenile idiopathic 
arthritis, and Castleman’s disease.43
Interleukin-5 is a cytokine with Th2 profile that stimu-
lates eosinophil production, activation, and maturation. 
Mepolizumab is an anti-IL-5 monoclonal antibody that has 
been investigated in patients with asthma, nasal polyps, and 
hypereosinophilic syndromes. Mepolizumab has been under 
investigation in Churg-Strauss syndrome on a phase I/II clinical 
trials.44 Interleukin-9 is a cytokine produced by Th2 and Th9 
cells and it is associated with higher bronchial hyperreactivity, 
having a pathogenic role in asthma. A humanized monoclonal 
anti-IL-9 (MEDI-528) antibody has been evaluated in the 
treatment of asthma.45
Interleukin-17 is a proinflammatory cytokine produced by 
Th17 cells with an important role in the immune response to 
specific pathogens, such as extracellular bacteria and fungi, 
an and the pathogenesis of autoimmune diseases, including 
RA. The safety of a monoclonal anti-IL-17 IgG4 antibody 
(LY2439821) has been demonstrated on a phase I study with 
RA patients.46
Interleukin-15 has an important role in the activation of TLs, 
including memory cells and NK cells. It has been shown that a 
monoclonal anti-IL-15 IgG1 antibody (HuMax-IL15) was well 
tolerated and effective in a phase I-II study in RA patients.47
The proinflammatory cytokines IL-12 and IL-23 share the 
same p40 subunit and they participate in the activation of NK 
cells and differentiation of CD4+ TLs into Th1 phenotype in 
response to IL-12, into Th17 in response to IL-23, along with 
the cytokines IL-1β, TGF-β, and IL-6. Two agents that affect 
the p40 subunit of IL-12 and IL-23 have been developed 
(ustekinumab and briakinumab), showing good results in the 
treatment of psoriasis.48 It has also been shown that ustekinu-
mab is effective in the treatment of psoriatic arthritis.49
Tumor growth factor β is a cytokine with three isoforms 
(TGF-β1, TGF-β2, and TGF-β3), but several proteins belong 
to the TGFβ superfamily. Aberrant expression of TGF-β1 and 
TGF-β2 is seen in patients with systemic sclerosis and it is 
implicated in the pathogenesis of cutaneous and pulmonary 
fibrosis. However, in a recent clinical assay, the use of an 
anti-TGF-β1 monoclonal antibody (CAT-192) did not show 
therapeutic efficacy in patients with systemic sclerosis.50 
Lederlimumab (CAT-152) is an anti-TGF-β2 human monoclo-
nal antibody  that has been studied in the postoperative period 
of trabeculectomy for the treatment of glaucoma to avoid ex-
cessive cicatrization, presenting controversial clinical results.51
In the family of type I interferons (IFN), recombinant IFNα 
and IFNβ proteins are used in clinical practice, especially in 
the treatment of viral hepatitis (hepatitis virus B and C)52,53 and 
multiple sclerosis, respectively. In the latter, the antagonism 
of IFNβ against IFNγ, which is very important in the patho-
physiology of multiple sclerosis,54 is the proposed mechanism 
of action. IFN-α has also been used in the treatment of muco-
cutaneous, ocular, and neurological manifestations of Behçet 
disease55 and Churg-Strauss syndrome.56 Fontolizumab is a 
humanized anti-IFNγ agent that has been evaluated in patients 
with CD, showing good results.
Receptor Activator for Nuclear Factor κ B Ligand 
(RANKL) is a cytokine of the IFNα superfamily, produced by 
activated T lymphocytes, that affects osteoclast differentiation 
and maturation, stimulating bone resorption. RANKL is im-
portant in the pathophysiology of RA, psoriatic arthritis, and 
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osteoporosis in systemic inflammatory disorders.58 Denosumab 
is an anti-RANKL human monoclonal antibody that has been 
investigated in the treatment of RA,58 osteoporosis,58,59 bone 
tumors, multiple myeloma, and bone metastasis.60
Biological therapy and the complement system
Eculizumab is a humanized anti-C5 monoclonal antibody that 
binds the 2b subunit of C5 convertase, blocking the cleavage 
of C5 into the proinflammatory component, C5a, as well 
as formation of the membrane attack complex (C5b-C9), 
therefore inhibiting cellular lysis.28 Eculizumab has been 
proven to be effective in the treatment of nocturnal paroxistic 
hemoglobinuria.61
Pexelizumab is a monoclonal antibody with high affinity 
for the C5 component and it also inhibits its cleavage by C5 
convertase. This biological agent has been investigated in pa-
tients with acute myocardial infarction, but has not shown to 
be effective in reducing the infarct area in patients undergoing 
primary angioplasty and data on the reduction of mortality in 
acute myocardial infarction are controversial.62
Anti-T lymphocyte biological therapy
Therapy with biological agents against therapeutic targets 
in TLs has been investigated extensively. Surface molecules 
[CD3, CD4, CD5, CD7, CD40 ligand (CD40L), and CD25] are 
the main targets; however, an indirect approach, i.e., against TL 
activation by inhibiting its interaction with antigen presenting 
cells and with B cells, can also be used.28
Abatacept is the main anti-TL biological agent currently 
being used. It inhibits co-stimulation-dependent activation of 
TLs by antigen presenting cells. Abatacept is a soluble fusion 
protein consisting of the extracellular domain of CTLA-4 
(cytotoxic T lymphocyte-associated antigen 4) linked to the 
Fc portion of human IgG1. It inhibits TL activation by binding 
to CD80 and CD86 molecules in antigen presenting cells, 
therefore blocking interaction with CD28 molecules in TLs. 
Since the affinity of CTLA-4 with CD80 and CD86 is much 
higher than that of CD28, abatacept hinders the binding of 
this molecule to CD80/86, preventing triggering of the second 
signal, which is fundamental for activation of TLs. Abatacept 
has been investigated extensively in RA with proven efficacy 
in several clinical trials. Some studies to evaluate the efficacy 
of abatacept in SLE, ANCA-associated vasculitis, giant cell 
arteritis, Takayasu arteritis, systemic sclerosis, and AS, are 
ongoing.64
The molecule of belatacept is similar to abatacept, but its 
affinity for CD80 and CD86 molecules is ten times higher than 
that of abatacept. Some studies in patients undergoing renal 
transplantation have demonstrated efficacy similar to that of 
cyclosporin in avoiding acute rejection and higher than cyclos-
porin in preventing post-transplantation chronic nephropathy.65
Ipilimumab and tremelimumab are anti-CTLA-4 mono-
clonal antibodies that increase activation of TLs and improve 
cancer immunity. Those agents have been evaluated in patients 
with melanoma and prostate, lung, and bladder neoplasias, 
besides hepatocellular carcinoma.66
Alefacept is another biological agent that inhibits interac-
tion between antigen presenting cells and T lymphocytes. It is 
a dimeric fusion protein composed by the extracellular portion 
of LFA-3 (leukocyte function antigen-3) and the Fc portion 
of IgG1. Alefacept binds the CD2 molecule in the surface of 
TLs, inhibiting its interaction with LFA-3, blocking TL acti-
vation. This agent has been successfully used in the treatment 
of psoriasis in patients with chronic lesions and indication of 
systemic therapy or phototherapy.67
Efalizumab is a monoclonal antibody anti-LFA-1 (leu-
kocyte functional antigen-1; an adhesion molecule present in 
T lymphocytes that binds to ICAM-1, allowing migration of 
activated T lymphocytes from the blood stream into tissues) 
monoclonal antibody. Efalizumab is currently indicated for 
treatment of psoriasis, but its use has been banned in the United 
States due to the increased risk of progressive multifocal 
leukoencephalopathy.67
Natalizumab is an anti-integrin α4β1 monoclonal antibody, 
a molecule found on the surface of leukocytes, except neutro-
phils. Natalizumab blocks the integration between integrin 
α4β1 and the adhesion molecule VCAM-1. The use of this 
biological agent has been investigated in the treatment of mul-
tiple sclerosis68 and CD69; however, the development of cases 
of progressive multifocal leukoencephalopathy indicates that 
it should be cautiously introduced in daily clinical practice.68
Anti-CD40L antibodies were developed to inhibit TL sti-
mulation by antigen presenting cells, and BL stimulation by 
T lymphocytes. Two anti-CD40L monoclonal antibodies have 
been investigated in patients with SLE. Hu5c9 was investigated 
in patients with lupus nephritis with good results, but the study 
was discontinued due to the development of thromboembolic 
phenomena. The other anti-CD40L antibody (IDEC 131) did not 
show benefits in the treatment of patients with lupus nephritis.70
Anti-TL therapy can be divided in depletion and modulation 
of its function. Several biological agents for depletion of TLs 
have been developed. The first was the anti-CD7 monoclonal 
antibody, but studies have been discontinued due to the lack 
of clinical efficacy of murine and chimeric antibodies in RA 
patients. CD5 plus is an immune conjugate composed of an 
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anti-CD5 murine antibody and the A chain of ricin toxin. 
Although open studies have demonstrated promising results, 
a controlled randomized clinical assay did not show benefits 
in the treatment of RA. Anti-CD4 (cM-T412) is another murine 
monoclonal antibody tested in RA, but clinical studies failed 
to show benefits from its use.28
Four non-T lymphocyte depleting anti-CD4 monoclonal 
antibodies, i.e., that modulate its function, have been developed. 
Compounds 4162W94 and IDEC-CE9.1/SB-210396 were the first to 
be investigated, but studies were discontinued due to adverse 
events. Studies with non-T lymphocyte depleting agents, anti-
CD4 Humax-CD4/HM6G IgG1 and anti-CD4 Mab OKT4-cdr4a, 
are ongoing. In transplant experimental models, the combined 
use of non-depleting anti-CD4 YTS177 and anti-CD8 YTS105 
antibodies has been investigated and results are promising.28
Visilizumab is a humanized anti-CD3 monoclonal antibody 
that induces apoptosis of activated TLs and several studies 
have demonstrated its safety and efficacy in the prevention of 
graft-versus-host disease (GVHD)71 and in the treatment of 
inflammatory bowel disease.69 Muronomab (OKT3) is another 
anti-CD3 antibody used to prevent graft rejection in patients 
who underwent transplantations.72
The interleukin-2 (IL-2) receptor in activated T lymphocytes 
(CD25) has also been the therapeutic target in some studies. IL2-
DAB (recombinant human IL-2 conjugated to the alpha chain of 
diphtheria toxin) showed good results in a study that evaluated 
RA patients, but a high frequency of elevated hepatic enzymes1 
was observed. Basiliximab and daclizumab are anti-IL-2 receptor 
monoclonal antibodies in activated T lymphocytes that have been 
used especially to prevent rejection in transplant patients.73,74
Alemtuzumab is an anti-CD52 monoclonal antibody; CD52 
is a molecule found on the surface of mature lymphocytes and 
monocytes. Alemtuzumab has been used in chronic lymphocytic 
leukemia and T cell cutaneous lymphoma.74 Recent studies de-
monstrate some benefits in the treatment of multiple sclerosis.74
Anti-b lymphocyte biological therapy
B lymphocytes have an important role in the pathogeny of 
several autoimmune diseases and this has stimulated the in-
vestigation of biological agents whose therapeutic actions lead 
to depletion of those cells or block its function. Currently, the 
main therapeutic targets in BLs include their surface mole-
cules (for example, CD20 and CD22), the cytokine BLyS (B 
lymphocyte stimulator), and APRIL (a proliferation-inducing 
ligand), besides its soluble receptor (TACI – transmembrane 
activator – activator and CAML interactor).77
Rituximab is the main drug developed and studied as anti-
BL therapy. It is an anti-CD20 chimeric monoclonal antibody. 
The CD20 molecule is found only on the surface of mature 
BLs and pre-B cells, and it is not found in germ cells or plasma 
cells. The use of rituximab causes selective depletion of BLs 
(CD20+) for up to 6 months, with recovery of normal levels 
in 9-12 months.77,78 Three main mechanisms are responsible 
for rituximab-induced BL depletion:78
•	 Antibody-mediated cellular cytotoxicity: NK 
cells, macrophages, and monocytes bind to the 
complex rituximab-CD20 on the cell surface through 
their Fcγ receptors, producing BL cytolysis.
•	 Complement-dependent cytotoxicity: the rituximab-
CD20 complex binds to C1q and activates the 
complement cascade via the classical pathway, leading 
to lysis of BLs by the membrane attack complex.
•	 Induction of BL CD20+ apoptosis.
In 1997, the use of rituximab in the treatment of non-Hodgkin's 
B cell lymphoma, follicular and low degree, refractory and re-
lapsing, was approved. After approval for its use in lymphoma, 
rituximab was used in other types of lymphoma, in B lym-
phocyte disorders (Wäldestrom macroglobulinemia and multiple 
myeloma), and in Castleman’s disease.77 The use of rituximab 
in the treatment of rheumatoid arthritis in patients who failed 
treatment with anti-TNFα has been approved. Rituximab has 
been investigated in the treatment of SLE in several case series 
and has presented varying results in controlling manifestations 
of the disease, especially refractory nephritis and neurologic 
involvement. It is curious that controlled clinical trials did not 
demonstrate efficacy in patients with nephritis or in patients with 
other SLE manifestations.79 Rituximab has been evaluated in two 
clinical trials in patients with Sjögren syndrome, demonstrating 
non-significant results regarding improvement of fatigue and 
xerostomia/xerophthalmia.80 Rituximab has been evaluated in 
systemic vasculitis, especially in patients with Wegener’s gra-
nulomatosis and microscopic polyangiitis, in two clinical assays 
that demonstrated it was not inferior to cyclophosphamide on 
inducing remission.81,82 It has shown promising results in other 
autoimmune diseases, such as immunologic thrombocytopenic 
purpura, type II mixed cryoglobulinemia, and inflammatory 
myopathies, in series of cases, representing future perspective 
of benefits with the use of this drug.78
Ocrelizumab is a second generation humanized anti-CD20 
monoclonal antibody that has the same specificity of rituxi-
mab.77 Phase III clinical trials to evaluate its efficacy in patients 
with non-Hodgkin's lymphoma are ongoing, but studies that 
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evaluated this agent in RA and SLE were discontinued due to 
lack of efficacy. A phase II study has been planned to evaluate 
the use of this agent in patients with reactivation and remission 
of multiple sclerosis.83
Ofatumumab and veltuzumab are anti-CD20 monoclonal 
antibodies that inhibit activation of B lymphocytes77 that are 
currently in phase III studies for chronic lymphocytic leukemia 
and non-Hodgkin lymphoma. In RA, ofatumumab has been 
evaluated in phase II studies with patients with inadequate 
response to methotrexate and anti-TNFα.84
Epratuzumab is a humanized anti-CD22 monoclonal antibo-
dy. CD22 is a surface glycoprotein restricted to B lymphocytes 
that regulates its activation and interaction com T lymphocytes. 
CD22 is found in the cytoplasm of pro- and pre-B lymphocytes, 
but it migrates to the surface in mature B lymphocytes, disa-
ppearing when it differentiates into plasmacells.77 The use of 
epratuzumab in relapsing non-Hodgkin lymphoma and in that 
refractory to conventional treatment, including rituximab, has 
been under investigation; it has also been investigated in SLE, 
Sjögren syndrome, and RA.85 Preliminary results have demons-
trated good tolerability and efficacy of this biological agent.86
Belimumab (LymphoStat-B) is a human monoclonal an-
tibody that specifically recognizes and inhibits the biological 
activity of BLyS (also known as BAFF), a molecule of the TNF 
superfamily that affects survival, maturation, and activation of B 
lymphocytes. Several cells (monocytes, macrophages, bone mar-
row stromal cells, synoviocytes, and astrocytes) produce BLyS, 
especially under interferon γ stimulation. Although belimumab 
is associated with a reduction in the number of circulating B 
lymphocytes, it only acts on soluble BLyS and it does not induce 
cytotoxicity.77,87 Phase II studies with belimumab are under way 
in patients with SLE and RA.88 In SLE, belimumab was well 
tolerated, but significant differences in disease activity and num-
ber of relapses were not observed when compared to placebo.89
Atacicept (TACI-Ig) is a recombinant fusion protein that 
simulates the soluble receptor (TACI) and blocks the action 
of BLyS and APRIL. This drug has been evaluated in a phase 
I study in SLE and good safety was observed in different do-
ses.90 Patients with SLE and RA are being recruited for phase 
II studies. Atacicept is also being evaluated in studies with 
patients with multiple sclerosis, chronic lymphocytic leukemia, 
multiple myeloma, and non-Hodgkin lymphoma.91
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